Autolus Therapeutics plc (NASDAQ:AUTL) Shares Sold by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD cut its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 23.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,939,241 shares of the company's stock after selling 902,261 shares during the quarter. Price T Rowe Associates Inc. MD owned 1.10% of Autolus Therapeutics worth $6,908,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Hennion & Walsh Asset Management Inc. purchased a new position in shares of Autolus Therapeutics during the fourth quarter valued at approximately $611,000. Renaissance Technologies LLC grew its holdings in shares of Autolus Therapeutics by 146.7% in the fourth quarter. Renaissance Technologies LLC now owns 618,942 shares of the company's stock worth $1,455,000 after purchasing an additional 368,071 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Autolus Therapeutics by 145.3% during the third quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company's stock valued at $4,663,000 after buying an additional 761,008 shares during the period. Handelsbanken Fonder AB lifted its holdings in shares of Autolus Therapeutics by 30.9% during the fourth quarter. Handelsbanken Fonder AB now owns 73,300 shares of the company's stock valued at $172,000 after purchasing an additional 17,300 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Autolus Therapeutics by 392.0% in the 4th quarter. Legal & General Group Plc now owns 297,736 shares of the company's stock worth $697,000 after purchasing an additional 237,224 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

Wall Street Analysts Forecast Growth

AUTL has been the topic of a number of recent analyst reports. Truist Financial decreased their target price on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Wells Fargo & Company decreased their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a report on Friday, March 21st. Finally, Needham & Company LLC reiterated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, April 10th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Autolus Therapeutics currently has an average rating of "Buy" and a consensus target price of $9.32.

Autolus Therapeutics Stock Performance

NASDAQ AUTL traded up $0.04 on Friday, reaching $1.39. 1,425,550 shares of the company's stock traded hands, compared to its average volume of 1,444,373. The stock has a 50 day moving average price of $1.54 and a 200-day moving average price of $2.28. The firm has a market cap of $368.54 million, a price-to-earnings ratio of -1.14 and a beta of 1.77. Autolus Therapeutics plc has a fifty-two week low of $1.11 and a fifty-two week high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). As a group, equities research analysts anticipate that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.